US 12,465,594 B2
Compositions and methods for the modulation of the corticotropin releasing factor binding protein and the treatment of alcohol use disorder
Carolina L. Haass-Koffler, Providence, RI (US); Douglas James Sheffler, San Diego, CA (US); and Nicholas David Peter Cosford, San Diego, CA (US)
Assigned to BROWN UNIVERSITY, Providence, RI (US); and SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, San Diego, CA (US)
Filed by Brown University, Providence, RI (US); and Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA (US)
Filed on Oct. 13, 2023, as Appl. No. 18/486,973.
Application 18/486,973 is a continuation of application No. 17/698,814, filed on Mar. 18, 2022, abandoned.
Application 17/698,814 is a continuation of application No. 17/273,607, granted, now 11,278,527, issued on Mar. 22, 2022, previously published as PCT/US2019/049498, filed on Sep. 4, 2019.
Claims priority of provisional application 62/726,830, filed on Sep. 4, 2018.
Prior Publication US 2024/0066009 A1, Feb. 29, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4245 (2006.01); A61K 31/517 (2006.01)
CPC A61K 31/4245 (2013.01) [A61K 31/517 (2013.01)] 4 Claims
 
1. A method of treating a stress response in a subject in need thereof, the method comprising the step of administering to the subject a composition comprising a therapeutically effective amount of a negative allosteric modulator (NAM) of the CRFBP (10 kD)-CRF2 complex, wherein the NAM is selected from a compound of the formula:

OG Complex Work Unit Chemistry
and
wherein the composition downregulates CRF-induced potentiation of N-Methyl-D-aspartic acid receptor (NMDAR)-mentioned synaptic transmission in dopamine neurons and/or increase postsynaptic gamma-aminobutyric acid (GABA) receptor function.